Dermata Therapeutics, Inc.

About Dermata Therapeutics, Inc.

Dermata is a clinical-stage biotechnology company founded in 2014, focused on developing innovative treatments for medical and aesthetic skin conditions and diseases with high unmet needs. Their strategy involves identifying and advancing products through clinical trials to demonstrate efficacy and safety, aiming to build a robust pipeline for conditions like acne, psoriasis, and rosacea, while creating value for stockholders and moving products from R&D to commercialization.

Products & Services

Product Pipeline:A range of innovative products targeting multiple dermatologic indications such as acne, psoriasis, and rosacea, utilizing a unique naturally derived technology with mechanical and chemical mechanisms of action.

Specialties

Treatment of medical and aesthetic skin conditions Development of innovative dermatologic products Focus on acne, psoriasis, and rosacea

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 4100000 MR: - FA: 4.1 million FAN: 4100000	D: 2025-12-29 FD: 2025-12-29	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 4100000 MR: - FA: $4.1 million FAN: 4100000	D: 2025-12-24 FD: 2025-12-24	1 investors
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 6200000 MR: - FA: $6.2 Million FAN: 6200000	D: 2025-03-27 FD: 2025-03-27	-
4	RT: Private Placement T: - FT: Private Placement	A: 2550000 MR: - FA: 2.55 million FAN: 2550000	D: 2025-01-23 FD: 2025-01-23	3 investors
5	RT: Private Placement T: - FT: Private Placement	A: 2550000 MR: - FA: $2.55 million FAN: 2550000	D: 2025-01-22 FD: 2025-01-22	1 investors
6	RT: Private Placement T: - FT: Private Placement	A: 3500000 MR: - FA: 3.5 million FAN: 3500000	D: 2024-09-17 FD: 2024-09-17	-
7	RT: Private Placement T: - FT: Private Placement	A: 3500000 MR: - FA: 3.5 million FAN: 3500000	D: 2024-09-16 FD: 2024-09-16	-
8	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2660000 MR: - FA: 2.66 million FAN: 2660000	D: 2024-05-17 FD: 2024-05-17	1 investors
9	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2260000 MR: - FA: 2.26 million FAN: 2260000	D: 2023-11-16 FD: 2023-11-16	-
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1800000 MR: - FA: $1.8 million FAN: 1800000	D: 2023-05-26 FD: 2023-05-26	1 investors
11	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1800000 MR: - FA: $1.8 million FAN: 1800000	D: 2023-05-24 FD: 2023-05-24	-
12	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2023-03-20 FD: 2023-03-20	1 investors
13	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2023-03-16 FD: 2023-03-16	1 investors

Private Placement Latest

2025-12-29

$4.1M

1 investor (Pro only)

Private Placement 2025-12-24

$4.1M

Warrant Exercise 2025-03-27

$6.2M

View 12 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gerry Proehl

Chairman, President, and CEO

M

Maria Bedoya Toro Munera

Senior Vice President, Regulatory Affairs and Quality Assurance

K

Kyri Van Hoose

Senior Vice President, Chief Financial Officer

C

Chris Nardo

Senior Vice President, Chief Development Officer

D

David Hale

Lead Director

K

Kathleen Scott

Director

View 8 more team members with Pro

Unlock Full Team Directory

Recent News